# Treatment Frequency Reduction in Pompe Disease

> **NCT06575829** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Pompe Disease (Late-onset)
- GAA Deficiency
- Glycogen Storage Disease Type II
- Acid Maltase Deficiency

## Interventions

- **DRUG:** Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks

## Key facts

- **NCT ID:** NCT06575829
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575829, "Treatment Frequency Reduction in Pompe Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06575829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*